相关临床试验
973
86 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1820
终止
114
11.7%
招募中
144
14.8%
暂停
3
0.3%
撤回
45
4.6%
进行中（未招募）
32
3.3%
Unknown
6
0.6%
已完成
575
59.1%
Enrolling By Invitation
23
2.4%
尚未招募
31
3.2%
暂无批准数据
- A randomized controlled trial of 180 primary care patients found that five-minute sessions of proximal intercessory prayer significantly reduced both pain and anxiety compared to music control. - Prayer recipients showed greater pain relief immediately and at two weeks, while anxiety improvements persisted for at least six weeks after the intervention. - Black participants experienced particularly large improvements in both pain and anxiety, with 97% of prayer recipients expressing willingness to have prayer available in future medical visits. - The intervention was safe with no adverse events reported, suggesting prayer may serve as a low-cost, non-pharmacologic complement to standard medical care.
- An Indiana University-led coalition has been selected for the NSF Regional Innovation Engines program, receiving $15 million over two years with potential for up to $160 million in sustained federal funding. - The NSF IMPACT Engine in Indiana aims to speed life-changing musculoskeletal innovations to market by connecting orthopedic industry leaders, top universities, and health data resources. - Nearly half of all Americans suffer from a chronic musculoskeletal disorder, underscoring the significant clinical need the initiative addresses. - The coalition aspires to train over 1,900 workers, launch more than 85 startups, bring at least 30 innovations to market, and deliver over $535 million in economic impact.
- Allarity Therapeutics has opened enrollment for a Phase 2 trial combining stenoparib with temozolomide for recurrent small cell lung cancer patients. - The trial is fully funded by the U.S. Department of Veterans Affairs and is now enrolling at 11 VA sites across the United States. - Stenoparib's dual PARP/tankyrase inhibition mechanism and favorable safety profile may overcome toxicity limitations seen with first-generation PARP inhibitors. - The combination targets both DNA repair pathways and WNT signaling, potentially offering enhanced anti-tumor activity for patients with limited treatment options.
- FDA Commissioner Martin Makary convened an expert panel on December 10, 2025, to discuss revising testosterone replacement therapy labeling, following the agency's recent removal of black box warnings from estrogen therapy products. - Experts argued that current prostate cancer contraindications and Schedule III controlled substance classification for testosterone are not supported by contemporary evidence and create unnecessary barriers to care. - The TRAVERSE trial, the largest randomized controlled trial on testosterone to date with 5,246 men, demonstrated non-inferiority for major adverse cardiovascular events compared to placebo (7.0% vs 7.3%). - Panel members recommended removing prostate cancer warnings, declassifying testosterone as a controlled substance, and broadening indications to align with professional society guidelines for men with symptoms and documented low testosterone levels.
- The combination of elranatamab and iberdomide demonstrated a 95.5% objective response rate with a 45.5% complete response rate in BCMA-naive patients with relapsed/refractory multiple myeloma in the phase 1b MagnetisMM-30 trial. - Responses occurred rapidly with a median time to response of 1.4 months, and the safety profile was manageable with expected toxicities including neutropenia, infections, and low-grade cytokine release syndrome. - Real-world data from 130 patients showed elranatamab maintains meaningful activity in heavily pretreated populations, with a 65% overall response rate despite less favorable baseline characteristics compared to clinical trials. - The combination's complementary mechanisms of action provide scientific rationale for improved efficacy, with iberdomide enhancing T-cell activation and proliferation to potentially optimize elranatamab's bispecific T-cell engagement.
- Eli Lilly and Company will provide up to $40 million to Indiana University over five years to expand clinical trial access and create an AI-enabled clinical trial infrastructure focused on Alzheimer's disease, diabetes, cancer, and cell and gene therapy. - The partnership aims to enhance clinical trial design, improve patient recruitment, and boost operational efficiency while leveraging IU Health's extensive provider network and expanding to additional health systems across Indiana. - The collaboration will accelerate access to neurological health resources with an initial focus on Alzheimer's disease, building on IU's neuroscience strengths and Lilly's global leadership in Alzheimer's innovation. - The initiative seeks to cultivate skilled talent for Indiana's $99 billion life sciences sector through co-developed programs that will prepare students for careers in biotechnology and pharmaceutical research.
- Indiana University receives $3.7 million NIDA grant to study ADHD medication effects on substance use disorders using Medicaid data from 3.3 million individuals aged 9-29. - Penn State secures $3.6 million NIMH grant to develop brain-based predictors for ADHD medication response in children with aggression and irritability. - Both studies address critical gaps in understanding ADHD treatment outcomes, with Indiana focusing on substance abuse risks and Penn State examining neurological response patterns. - The research aims to improve personalized treatment approaches and reduce reliance on higher-risk interventions like antipsychotic medications.
- Researchers demonstrated for the first time that alternate-day fasting increases the efficacy of anti-androgen therapy in prostate cancer through preclinical mouse models. - The study found that intermittent fasting reduces androgen receptor expression and signaling, enhancing the antitumor activity of enzalutamide by reducing amino acid levels and protein synthesis. - Clinical trials are now underway to evaluate restricted eating patterns in prostate cancer patients receiving hormone therapy and plant-based diets for cancer patients on chemotherapy.
- Tulsi Therapeutics completed the world's first successful animal trial of a novel stem cell-exosome combination therapy for chronic liver failure, achieving 100% liver fibrosis reversal with zero deaths. - The investigational product Tulsi-28X, derived from Wharton's Jelly mesenchymal stem cells and their native exosomes, represents a first-in-class regenerative therapy never before tested in any animal model worldwide. - Results showed dramatic efficacy compared to controls, with only 14% reversal and 43% deaths in untreated animals, positioning the therapy as a potential paradigm shift for liver disease treatment. - The company plans to advance Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences, targeting a disease that contributes to nearly 20% of global liver-related deaths.
- A Swedish population study of 247,420 individuals found that ADHD medications consistently reduced risks of self-harm, unintentional injury, traffic crashes, and crime across all age groups and sexes. - The protective effects of ADHD medications weakened over time as prescription rates increased from 0.6% to 2.8% between 2006 and 2020, particularly for unintentional injury, traffic crashes, and crime. - Changes in patient demographics did not fully explain the diminishing benefits, highlighting the need for ongoing evaluation of medication use and patient selection as prescribing expands. - The findings suggest that while ADHD medications remain beneficial, the real-world outcomes may be affected by shifts in the patient population receiving treatment.
